abo-incompatible-living-donor-liver-transplantation-in-a-patient-with-a-history-of-platelet-transfusion-related-anaphylaxis-archives-of-clinical-gastroenterology-peertechz-journals

•Download as PPTX, PDF•

0 likes•53 views

This document summarizes a case report of a successful ABO-incompatible living donor liver transplantation performed on a patient with a history of platelet transfusion-related anaphylaxis. The patient had hepatitis B virus-related liver cirrhosis and hepatocellular carcinoma. Liver transplantation often requires significant blood loss and transfusions. However, this presented a high risk for the patient due to their previous anaphylactic reaction to platelet transfusions. Despite these risks, the transplantation was performed successfully with no allergic transfusion reactions in the patient.

Science

Archives of Clinical
Gastroenterology
ISSN: 2455-2283
Peertechz Journals

Case Report
ABO-incompatible living donor liver
transplantation in a patient with a history of
platelet transfusion-related anaphylaxis
 Won-Bae Chang, Ho-Seong Han*, Jai Young Cho, Yoo-Seok Yoon, Young
Rok Choi and Bo-Ram Lee
 *Corresponding author: Ho-Seong Han, Department of Surgery,
Seoul National University College of Medicine, Seoul National
University, Bundang Hospital, Seongnam, South Korea, 173, 82 Gumi-
ro, Bundang-gu, Seongnam, Gyeonggi, South Korea, 463-707, Tel: 82-
31-787-7091
 Dates: Received: 08 April, 2016; Accepted: 28 April, 2016; Published:
30 April, 2016
 Citation: Chang WB, Han HS, Cho JY, Yoon YS, Choi YR, et al. (2016)
ABO-incompatible living donor liver transplantation in a patient with
a history of platelet transfusion-related anaphylaxis. Arch Clin
Gastroenterol 2(1): 010-012.

Abstract
 Anaphylaxis and severe allergic transfusion reactions (ATR)
are uncommon omplications after blood transfusion.
Nevertheless, these complications are associated with very
severe outcomes, such as dyspnea, shock, and death.
Patients with end-stage liver disease who require liver
transplantation have a high tendency for bleeding because
of splenomegaly-induced hrombocytopenia and decreased
production of coagulation factors in the liver. Liver
transplantation is a very long procedure and a significant
perioperative blood loss is highly likely. Therefore,
transfusion of platelets and other blood products is often
necessary. We report a successful ABO-incompatible living
donor liver transplantation in a patient with hepatitis B
virus-related liver cirrhosis and hepatocellular carcinoma
who had a history of platelet transfusion-related d
anaphylaxis.

Thank you
For more information Read Online Article…
http://www.peertechz.com/Clinical-Gastroenterology/pdf/ACG-2-112.pdf
For
Full
Article
PDF

What's hot

The Storage Sciences, Blood Transfusion and Expected Disorders Revisited_ Cri...

CrimsonpublishersABTD

Crimson Publishers-Spotlights on CLEAR III

CrimsonPublishersTNN

Room a a07. mcgee-procalcitonin to predict ss and guide therapy_(en)

SoM

A case of back pain with resistant hypertension resulting from an anomalous a...

Jack Michel MD

Evolution of interventional nephrology. prof. hussein sheashaa (1)

FarragBahbah

Outcome of hemodialysis avf in iraq pdf

Abdulsalam Taha

Advancing Dialysis - Intensive Hemodialysis

nxstage

Borzio2016 (1)

Javier Gonzalez

PORTAL HYPERTENSIVE GASTROPATHY

Pratap Tiwari

Riñon pulmon

Gisela Subils

Ojchd.000537

crimsonpublishersOJCHD

Nia (1)

Breno Gois

What's hot (12)

The Storage Sciences, Blood Transfusion and Expected Disorders Revisited_ Cri...

Crimson Publishers-Spotlights on CLEAR III

Room a a07. mcgee-procalcitonin to predict ss and guide therapy_(en)

A case of back pain with resistant hypertension resulting from an anomalous a...

Evolution of interventional nephrology. prof. hussein sheashaa (1)

Outcome of hemodialysis avf in iraq pdf

Advancing Dialysis - Intensive Hemodialysis

Borzio2016 (1)

PORTAL HYPERTENSIVE GASTROPATHY

Riñon pulmon

Ojchd.000537

Nia (1)

Viewers also liked

Rewrite your Story / Change your Future

Alexandros R. Besmak

Why Own Safeguard? - Full Value Yet to be Realized - Ownership Stakes in Exciting Partner Companies - Top Performance of Proven Team - Financial Strength, Flexibility and Liquidity - Strong Alignment of Interests Forward-Looking Statements Statements contained in this presentation that are not historical facts are forward looking statements which involve certain risks and uncertainties including, but not limited to, risks associated with the uncertainty of managing rapidly changing technologies, limited access to capital, competition, the ability to attract and retain qualified employees, our ability to execute our strategy, the uncertainty of the future performance of our partner companies, acquisitions and dispositions of additional partner companies, the inability to manage growth, government regulation and legal liabilities and the effect of economic conditions in the business sectors in which our partner companies operate, negative media coverage and other uncertainties as described in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K. Safeguard does not assume any obligation to update any forward looking statements or other information contained in this presentation.

Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - June 2012

Safeguard Scientifics

Antoni tàpies.alexandra

IES Lluis Companys

For 60 years, Safeguard Scientifics (NYSE:SFE) has been synonymous with entrepreneurship and innovation. Safeguard’s distinguished track record includes market leaders such as QVC, Novell, Cambridge Technology Partners, CompuCom, ICG, Traffic.com, Avid Radiopharmaceuticals, Portico Systems and more! Today, Safeguard provides capital and operational support to early- and growth-stage healthcare and technology companies specifically in medtech, healthtech, specialty pharma, fintech, digital media and enterprise 3.0. As of September 30, 2013, Safeguard's portfolio consists of 22 companies which are projected to generate aggregate revenue of $285M-$295M in 2013, a 44% to 49% increase YoY. Safeguard targets to increase its stable of partner companies to 25 by YE'13, deploy capital with greater consistency, and achieve monetizations with aggregate cash-on-cash returns at a minimum of 2x cost. Through keen focus and consistent execution, Safeguard believes that it can drive its capital under management to a range of $550M-$700M by YE'15. Statements contained in this presentation that are not historical facts are forward looking statements which involve certain risks and uncertainties including, but not limited to, risks associated with our ability to make good decisions about the deployment of capital, the fact that our partner companies may vary from period to period, our substantial capital requirements and absence of liquidity from our partner company holdings, fluctuations in the market prices of our publicly traded partner company holdings, competition, our inability to obtain maximum value for our partner company holdings, our ability to attract and retain qualified employees, market valuations in sectors in which our partner companies operate may decline, our inability to control our partner companies, our need to manage our assets to avoid registration under the Investment Company Act of 1940, and risks associated with our partner companies, including the fact that most of our partner companies have a limited history and a history of operating losses, face intense competition and may never be profitable, the effect of economic conditions in the business sectors in which our partner companies operate, and other uncertainties as described in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K. Safeguard does not assume any obligation to update any forward looking statements or other information contained in this presentation.

Safeguard Scientifics (NYSE:SFE) Corporate Presentation - December 2013

Safeguard Scientifics

Mobile for B2B: Native or Web?

Omobono

Space and stock infographic

Access Group

Safeguard Scientifics Announces Fourth Quarter and Full-Year 2011 Financial Results For the complete Q4 and FY'11 Press release, click here: http://www.safeguard.com/safeguard-scientifics-announces-fourth-quarter-and-full-year-2011-financial-results Forward-Looking Statements Statements contained in this presentation that are not historical facts are forward looking statements which involve certain risks and uncertainties including, but not limited to, risks associated with the uncertainty of managing rapidly changing technologies, limited access to capital, competition, the ability to attract and retain qualified employees, our ability to execute our strategy, the uncertainty of the future performance of our partner companies, acquisitions and dispositions of additional partner companies, the inability to manage growth, government regulation and legal liabilities and the effect of economic conditions in the business sectors in which our partner companies operate, negative media coverage and other uncertainties as described in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K. Safeguard does not assume any obligation to update any forward looking statements or other information contained in this presentation.

Safeguard Scientifics Q4 and FY'11 Results Presentation

Safeguard Scientifics

How Social Media enables the Job Search

Shannon Eastman

ANTONI TÀPIES

IES Lluis Companys

Resultats de l_enquesta_sobre

IES Lluis Companys

How to Become your own Future Strategist

Alexandros R. Besmak

Taller de reciclatge

IES Lluis Companys

Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - November ...

Safeguard Scientifics

Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - January 2012

Safeguard Scientifics

Rap CTI - Brochure

Acqueon Technologies Inc.

Resultats enquestes powerpoint

IES Lluis Companys

Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - April 2012

Safeguard Scientifics

Leadership. Invest in the Future (Generation)

Alexandros R. Besmak

Perusal (click on "Full" lower right)

nordtech

Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - January 2012

Safeguard Scientifics

Viewers also liked (20)

Rewrite your Story / Change your Future

Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - June 2012

Antoni tàpies.alexandra

Safeguard Scientifics (NYSE:SFE) Corporate Presentation - December 2013

Mobile for B2B: Native or Web?

Space and stock infographic

Safeguard Scientifics Q4 and FY'11 Results Presentation

How Social Media enables the Job Search

ANTONI TÀPIES

Resultats de l_enquesta_sobre

How to Become your own Future Strategist

Taller de reciclatge

Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - November ...

Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - January 2012

Rap CTI - Brochure

Resultats enquestes powerpoint

Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - April 2012

Leadership. Invest in the Future (Generation)

Perusal (click on "Full" lower right)

Safeguard Scientifics (NYSE: SFE) Investor Relations Presentation - January 2012

Similar to abo-incompatible-living-donor-liver-transplantation-in-a-patient-with-a-history-of-platelet-transfusion-related-anaphylaxis-archives-of-clinical-gastroenterology-peertechz-journals

Gut edema in acute illness is not yet sufficiently studied and existing knowledge is largely based on experimental animal studies or small studies in healthy volunteers. However, increasing evidence confirms that gut edema impairs intestinal motility and healing of bowel anastomoses, being therefore an important contributor to outcome. Current presentation focuses mainly on the role of fluids in development of intestinal edema.

Pathophysiological mechanisms and consequences of gut edema (Annika Reintam W...

WSACS

Donor assessment

أحمد عبد الوهاب الجندي

Analyses of Risk Factors of Diarrhea in Patients with Esophagectomy

semualkaira

Analyses of Risk Factors of Diarrhea in Patients with Esophagectomy

semualkaira

Fluoroquinolone resistant rectal colonization predicts risk of infectious com...

TC İÜ İTF Üroloji AD

Upper GI Bleeding is defined as Bleeding from GIT starting from oral cavity upto Ligamentum of trietz .,it may be either a hematemesis, malena or both. Upper GI bleed is a quiet common problem seen in day to day Gastroenterology OPD., & a detailed 5yrs study was made to assess the etiological factors for UGI bleeding in the period from 2009-2014, in the department of Gastroenterology ,GGH/Guntur Medical college, Guntur,AP.

Evaluation Of Aetiology Of Upper Gastro Intestinal Bleeding &Management In Th...

iosrjce

portal bilioathy

Sujan Shrestha

Eosinophilic esophagitis

Chulalongkorn Allergy and Clinical Immunology Research Group

Pseudoaneurysms arising from hepatic artery

Ashok Thorat

Jonathan G Stine, Puja M Shah, Scott L Cornella, Sean R Rudnick, Marwan S Ghabril, George J Stukenborg, Patrick G Northup Jonathan G Stine, Sean R Rudnick, Patrick G Northup, Division of Gastroenterology and Hepatology, University of Virginia, Charlottesville, VA 22908, United States Puja M Shah, Department of Surgery, University of Virginia, Charlottesville, VA 22908, United States Scott L Cornella, Department of Medicine, University of Virginia, Charlottesville, VA 22908, United States Marwan S Ghabril, Division of Gastroenterology and Hepatology, Indiana University, Indianapolis, IN 46202, United States George J Stukenborg, Department of Public Health Science, University of Virginia, Charlottesville, VA 22908, United States Author contributions: Stine JG and Shah PM contributed equally to this work; Stine JG, Shah PM, Ghabril MS, Stukenborg GJ and Northup PG designed research; Stine JG, Shah PM, Cornella SL and Rudnick SR performed research; Stine JG and Shah PM analyzed data; Stine JG, Shah PM, Cornella SL, Rudnick SR, Ghabril MS, Stukenborg GJ and Northup PG wrote the paper. Supported by (In part) grant funding from the National Institutes of Health (Grant 5T32DK007769-15); and NIH- Surgical Oncology grant (T32 CA163177). Conflict-of-interest statement: We have no conflicts of interest to report. Data sharing statement: No additional data are available. Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/ licenses/by-nc/4.0/ Correspondence to: Jonathan G Stine, MD, MSc, Division of Gastroenterology and Hepatology, University of Virginia, JPA and Lee Street, MSB 2145, PO Box 800708, Charlottesville, VA 22908, United States. [email protected] Telephone: +1-434-9242959 Fax: +1-434-2447529 Received: September 18, 2015 Peer-review started: September 19, 2015 First decision: October 21, 2015 Revised: November 2, 2015 Accepted: November 10, 2015 Article in press: November 11, 2015 Published online: November 28, 2015 Abstract AIM: To determine the clinical impact of portal vein thrombosis in terms of both mortality and hepatic decompensations (variceal hemorrhage, ascites, por- tosystemic encephalopathy) in adult patients with cirrhosis. METHODS: We identified original articles reported through February 2015 in MEDLINE, Scopus, Science Citation Index, AMED, the Cochrane Library, and relevant examples available in the grey literature. Two independent reviewers screened all citations for inclu- sion criteria and extracted summary data. Random effects odds rati ...

Jonathan G Stine, Puja M Shah, Scott L Cornella, Sean R Rudnic.docx

priestmanmable

1._Outcome_and_Complications_of_ABO_Mismatch_Hematopoietic_Stem_Cell_Transpla...

AllAboutECG

Extra hepatic portal vein obstruction (EHPVO) is the commonest cause of portal hypertension in children. EHPVO along with thrombosis of splenic vein (SV) and superior mesenteric vein (SMV) is an uncommon condition causing extensive varices formation in the oesophagus, stomach and in other parts of gastrointestinal tract including rectal varix as well as splenomegaly and associated hypersplenism. Most commonly the child presents with hematmesis and due to extensive varices it is difficult to obliterate the varices using endoscopic therapy. Due to thrombosed SMV and SV shunt surgery is not possible. We describe here a case of EHPVO with SMV and SV thrombosis with bleeding gastric varix that underwent gastro- oesophageal devascularisation with splenectomy and oesophageal transection to prevent recurrent bleed from gastric varices.

Extra Hepatic Portal Vein Obstruction (EHPVO) with Extensive Mesenteric Venou...

Apollo Hospitals

Primary Biliary Cholangitis

Pratap Tiwari

Renal resistive index in mouse model: Asian Journal of Urology: Crimson Publi...

CrimsonPublishersUrologyJournal

The Role of PPIS Which One is The Best for Acute Upper GI Bleeding?

Mangatas Manalu-Tiga

Yu Zhou_CV_1507

Yu Zhou

Role of Stem Cell Transplantation in the Treatment of Ulcerative Colitis

Mohammed Fathy Zaky

Cholecystectomy in patient with Liver Cirrhosis.pptx

Pushpa Lal Bhadel

Upper Gastrointestinal Bleeding (UGIB) - General Approach

Mohamed Badheeb

Similar to abo-incompatible-living-donor-liver-transplantation-in-a-patient-with-a-history-of-platelet-transfusion-related-anaphylaxis-archives-of-clinical-gastroenterology-peertechz-journals (19)

Pathophysiological mechanisms and consequences of gut edema (Annika Reintam W...

Donor assessment

Analyses of Risk Factors of Diarrhea in Patients with Esophagectomy

Fluoroquinolone resistant rectal colonization predicts risk of infectious com...

Evaluation Of Aetiology Of Upper Gastro Intestinal Bleeding &Management In Th...

portal bilioathy

Eosinophilic esophagitis

Pseudoaneurysms arising from hepatic artery

Jonathan G Stine, Puja M Shah, Scott L Cornella, Sean R Rudnic.docx

1._Outcome_and_Complications_of_ABO_Mismatch_Hematopoietic_Stem_Cell_Transpla...

Extra Hepatic Portal Vein Obstruction (EHPVO) with Extensive Mesenteric Venou...

Primary Biliary Cholangitis

Renal resistive index in mouse model: Asian Journal of Urology: Crimson Publi...

The Role of PPIS Which One is The Best for Acute Upper GI Bleeding?

Yu Zhou_CV_1507

Role of Stem Cell Transplantation in the Treatment of Ulcerative Colitis

Cholecystectomy in patient with Liver Cirrhosis.pptx

Upper Gastrointestinal Bleeding (UGIB) - General Approach

Recently uploaded

PHOTOSYNTHETIC BACTERIA (OXYGENIC AND ANOXYGENIC)

kushbuR

RACEMIzATION AND ISOMERISATION completed.pptx

ArunLakshmiMeenakshi

Taphonomy is the study of how organisms decay and become fossilized or preserved in the paleontological record. The term taphonomy (from Greek táphos, τάφος 'burial' and nomos, νόμος 'law') was introduced to paleontology in 1940[1] by Soviet scientist Ivan Efremov to describe the study of the transition of remains, parts, or products of organisms from the biosphere to the lithosphere.[2][3] The term taphomorph is used to describe fossil structures that represent poorly-preserved, deteriorated remains of a mixture of taxonomic groups, rather than of a single one.

Taphonomy and Quality of the Fossil Record

Sangram Sahoo

Electricity and Circuits for Grade 9 students

levieagacer

Fun for mover student's book- English book for teaching.pdf

hoangquan21999

Film Coated Tablet and Film Coating raw materials.pdf

Pharmatech-rx

Soil and Water Conservation Engineering (SWCE) is a specialized field of stud...

yogeshlabana357357

Molecular and Cellular Mechanism of Action of Hormones such as Growth Hormone...

Ansari Aashif Raza Mohd Imtiyaz

Vital Signs of Animals Presentation By Aftab Ahmed Rahimoon

intarciacompanies

ABHISHEK ANTIBIOTICS PPT MICROBIOLOGY // USES OF ANTIOBIOTICS TYPES OF ANTIB...

ABHISHEK SONI NIMT INSTITUTE OF MEDICAL AND PARAMEDCIAL SCIENCES , GOVT PG COLLEGE NOIDA

NUMERICAL Proof Of TIme Electron Theory.

syedmuneemqadri

VILLAGE ATTACHMENT For rural agriculture PPT.pptx

AQIBRASOOL4

Factor Causing low production and physiology of mamary Gland

Rcvets

Classification of Kerogen, Perspective on palynofacies in depositional envi...

Sangram Sahoo

This edition of our Newsletter is a testament to our collective dedication and the exciting progress we’ve achieved. The completion of our first Periodic Report marks a significant milestone, and the advancements in tetrahedrite mineral-based thermoelectric materials are not just promising -they are a lap towards a sustainable future. We’re excited to share updates on our ongoing activities, our synergistic collaborations with the EHRASE cluster and THERMOS project, and insightful technical information on thermoelectric generators. But that’s not all, join us on the Consortium Tour, where this time SGUDS and IGME-CSIC take centre stage. Plus, don’t miss the insightful interview with Doug Crane from our Scientific Advisory Board, whose expertise enriches our understanding of thermoelectrics. This edition also features the fascinating adventures of Starty, exploring the practical uses of thermoelectric devices in a narrative that’s both educational and engaging. Looking ahead, we eagerly anticipate your visit to the START booth at the upcoming 40th International and 20th European Thermoelectric Conference, ICT/ECT 2024, in Krakow. We hope this Newsletter serves not only as a source of information but also as an inspiration for continued excellence. Stay connected with us for more exciting updates from START on our website and social media channels.

EU START PROJECT. START-Newsletter_Issue_4.pdf

Start Project

Marine and terrestrial biogeochemical models are key components of the Earth System Models (ESMs) used toproject future environmental changes. However, their slow adjustment time also hinders effective use of ESMsbecause of the enormous computational resources required to integrate them to a pre-industrial equilibrium. Here,a solution to this "spin-up" problem based on "sequence acceleration", is shown to accelerate equilibration of state-of-the-art marine biogeochemical models by over an order of magnitude. The technique can be applied in a "blackbox" fashion to existing models. Even under the challenging spin-up protocols used for Intergovernmental Panelon Climate Change (IPCC) simulations, this algorithm is 5 times faster. Preliminary results suggest that terrestrialmodels can be similarly accelerated, enabling a quantification of major parametric uncertainties in ESMs, improvedestimates of metrics such as climate sensitivity, and higher model resolution than currently feasible.

Efficient spin-up of Earth System Models usingsequence acceleration

Sérgio Sacani

SaffronCrocusGenomicsThessalonikiOnlineMay2024TalkOnline.pptx

Pat (JS) Heslop-Harrison

Harry Coumnas asserts that some individuals think teleportation is merely a fantastical concept and that human teleportation seems like science fiction in real life. However, scientists have already made headway toward the goal of human teleportation by successfully achieving quantum teleportation. He takes into account the reality that, although teleportation for humans is confined to science fiction, it is conceivable in the subatomic realm of quantum mechanics.

Harry Coumnas Thinks That Human Teleportation is Possible in Quantum Mechanic...

kevin8smith

Nanoparticles for the Treatment of Alzheimer’s Disease_102718.pptx

ssusera4ec7b

ManganesehasbeenobservedonMarsbytheNASACuriosityroverinavarietyofcontextsand isanimportantindicatorofredoxprocessesinhydrologicsystemsonEarth.WithintheMurrayformation,an ancientprimarilyfine‐grainedlacustrinesedimentarydeposit inGalecrater,Mars,haveobservedupto45× enrichmentinmanganeseandupto1.5×enrichmentinironwithincoarsergrainedbedrocktargetscomparedto themeanMurraysedimentcomposition.Thisenrichment inmanganesecoincideswiththetransitionbetween twostratigraphicunitswithintheMurray:SuttonIsland, interpretedasalakemarginenvironment,andBlunts Point,interpretedasalakeenvironment.OnEarth,lacustrineenvironmentsarecommonlocationsofmanganese precipitationduetohighlyoxidizingconditionsinthelakes.Here,weexplorethreemechanismsfor ferromanganeseoxideprecipitationatthislocation:authigenicprecipitationfromlakewateralongalakeshore, authigenicprecipitationfromreducedgroundwaterdischargingthroughporoussandsalongalakeshore,and earlydiageneticprecipitationfromgroundwaterthroughporoussands.All threescenariosrequirehighly oxidizingconditionsandwediscussoxidantsthatmayberesponsiblefortheoxidationandprecipitationof manganeseoxides.Thisworkhasimportant implicationsforthehabitabilityofMarstomicrobesthatcould haveusedMnredoxreactions,owingtoitsmultipleredoxstates,asanenergysourceformetabolism.

Manganese‐RichSandstonesasanIndicatorofAncientOxic LakeWaterConditionsinGale...

Sérgio Sacani

Recently uploaded (20)

PHOTOSYNTHETIC BACTERIA (OXYGENIC AND ANOXYGENIC)

RACEMIzATION AND ISOMERISATION completed.pptx

Taphonomy and Quality of the Fossil Record

Electricity and Circuits for Grade 9 students

Fun for mover student's book- English book for teaching.pdf

Film Coated Tablet and Film Coating raw materials.pdf

Soil and Water Conservation Engineering (SWCE) is a specialized field of stud...

Molecular and Cellular Mechanism of Action of Hormones such as Growth Hormone...

Vital Signs of Animals Presentation By Aftab Ahmed Rahimoon

ABHISHEK ANTIBIOTICS PPT MICROBIOLOGY // USES OF ANTIOBIOTICS TYPES OF ANTIB...

NUMERICAL Proof Of TIme Electron Theory.

VILLAGE ATTACHMENT For rural agriculture PPT.pptx

Factor Causing low production and physiology of mamary Gland

Classification of Kerogen, Perspective on palynofacies in depositional envi...

EU START PROJECT. START-Newsletter_Issue_4.pdf

Efficient spin-up of Earth System Models usingsequence acceleration

SaffronCrocusGenomicsThessalonikiOnlineMay2024TalkOnline.pptx

Harry Coumnas Thinks That Human Teleportation is Possible in Quantum Mechanic...

Nanoparticles for the Treatment of Alzheimer’s Disease_102718.pptx

Manganese‐RichSandstonesasanIndicatorofAncientOxic LakeWaterConditionsinGale...

abo-incompatible-living-donor-liver-transplantation-in-a-patient-with-a-history-of-platelet-transfusion-related-anaphylaxis-archives-of-clinical-gastroenterology-peertechz-journals

1. Archives of Clinical Gastroenterology ISSN: 2455-2283 Peertechz Journals

2. Case Report ABO-incompatible living donor liver transplantation in a patient with a history of platelet transfusion-related anaphylaxis  Won-Bae Chang, Ho-Seong Han*, Jai Young Cho, Yoo-Seok Yoon, Young Rok Choi and Bo-Ram Lee  *Corresponding author: Ho-Seong Han, Department of Surgery, Seoul National University College of Medicine, Seoul National University, Bundang Hospital, Seongnam, South Korea, 173, 82 Gumi- ro, Bundang-gu, Seongnam, Gyeonggi, South Korea, 463-707, Tel: 82- 31-787-7091  Dates: Received: 08 April, 2016; Accepted: 28 April, 2016; Published: 30 April, 2016  Citation: Chang WB, Han HS, Cho JY, Yoon YS, Choi YR, et al. (2016) ABO-incompatible living donor liver transplantation in a patient with a history of platelet transfusion-related anaphylaxis. Arch Clin Gastroenterol 2(1): 010-012.

3. Abstract  Anaphylaxis and severe allergic transfusion reactions (ATR) are uncommon omplications after blood transfusion. Nevertheless, these complications are associated with very severe outcomes, such as dyspnea, shock, and death. Patients with end-stage liver disease who require liver transplantation have a high tendency for bleeding because of splenomegaly-induced hrombocytopenia and decreased production of coagulation factors in the liver. Liver transplantation is a very long procedure and a significant perioperative blood loss is highly likely. Therefore, transfusion of platelets and other blood products is often necessary. We report a successful ABO-incompatible living donor liver transplantation in a patient with hepatitis B virus-related liver cirrhosis and hepatocellular carcinoma who had a history of platelet transfusion-related d anaphylaxis.

4. Thank you For more information Read Online Article… http://www.peertechz.com/Clinical-Gastroenterology/pdf/ACG-2-112.pdf For Full Article PDF

abo-incompatible-living-donor-liver-transplantation-in-a-patient-with-a-history-of-platelet-transfusion-related-anaphylaxis-archives-of-clinical-gastroenterology-peertechz-journals

Recommended

Recommended

More Related Content

What's hot

What's hot (12)

Viewers also liked

Viewers also liked (20)

Similar to abo-incompatible-living-donor-liver-transplantation-in-a-patient-with-a-history-of-platelet-transfusion-related-anaphylaxis-archives-of-clinical-gastroenterology-peertechz-journals

Similar to abo-incompatible-living-donor-liver-transplantation-in-a-patient-with-a-history-of-platelet-transfusion-related-anaphylaxis-archives-of-clinical-gastroenterology-peertechz-journals (19)

Recently uploaded

Recently uploaded (20)

abo-incompatible-living-donor-liver-transplantation-in-a-patient-with-a-history-of-platelet-transfusion-related-anaphylaxis-archives-of-clinical-gastroenterology-peertechz-journals